Fiera Capital Corp Has $5.89 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Fiera Capital Corp grew its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 0.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 677,038 shares of the company’s stock after acquiring an additional 5,920 shares during the quarter. Fiera Capital Corp owned 1.30% of EyePoint Pharmaceuticals worth $5,890,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Ameritas Investment Partners Inc. raised its holdings in shares of EyePoint Pharmaceuticals by 44.0% during the first quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock worth $77,000 after acquiring an additional 1,136 shares during the period. Greenwich Wealth Management LLC bought a new position in EyePoint Pharmaceuticals during the 2nd quarter worth about $94,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of EyePoint Pharmaceuticals by 271.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock valued at $95,000 after purchasing an additional 7,953 shares during the period. Arizona State Retirement System lifted its holdings in shares of EyePoint Pharmaceuticals by 9.7% in the second quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $115,000 after purchasing an additional 1,171 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of EyePoint Pharmaceuticals by 129.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,393 shares of the company’s stock worth $194,000 after buying an additional 5,308 shares during the period. Institutional investors and hedge funds own 99.41% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Chardan Capital reissued a “buy” rating and issued a $28.00 target price on shares of EyePoint Pharmaceuticals in a research report on Friday, June 28th. JPMorgan Chase & Co. lowered their price objective on shares of EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Jefferies Financial Group started coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They set a “buy” rating and a $15.00 target price for the company. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Saturday, September 21st. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to MarketBeat, EyePoint Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $30.57.

EyePoint Pharmaceuticals Stock Performance

Shares of EYPT stock opened at $7.98 on Monday. EyePoint Pharmaceuticals, Inc. has a 52-week low of $5.67 and a 52-week high of $30.99. The stock has a market cap of $427.09 million, a price-to-earnings ratio of -4.38 and a beta of 1.59. The firm’s 50-day moving average is $8.70 and its 200-day moving average is $12.19.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.03). EyePoint Pharmaceuticals had a negative net margin of 172.29% and a negative return on equity of 43.24%. The business had revenue of $9.48 million during the quarter, compared to the consensus estimate of $11.61 million. Sell-side analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Insider Buying and Selling at EyePoint Pharmaceuticals

In other EyePoint Pharmaceuticals news, Director David R. Guyer sold 11,625 shares of the company’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $10.06, for a total value of $116,947.50. Following the transaction, the director now directly owns 1,850 shares in the company, valued at $18,611. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.74% of the company’s stock.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.